


Healthcare | Mid Cap
J B Chemicals & Pharmaceuticals Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a very strong, low-debt financial structure. The company excels at generating profits from its sales and provides excellent returns to its shareholders. Its growth in revenue and earnings is remarkable, indicating a strong market position. The company is highly solvent, meaning it has a very low risk associated with debt. The primary area of weakness is in operational efficiency, where the use of assets to generate sales is less effective. While its ability to meet short-term obligations is generally good, its immediate cash reserves are more limited. The future outlook is positive, driven by strong growth and profitability, though its operational efficiency lags behind its otherwise stellar financial performance.
J B Chemicals & Pharmaceuticals Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a very strong, low-debt financial structure. The company excels at generating profits from its sales and provides excellent returns to its shareholders. Its growth in revenue and earnings is remarkable, indicating a strong market position. The company is highly solvent, meaning it has a very low risk associated with debt. The primary area of weakness is in operational efficiency, where the use of assets to generate sales is less effective. While its ability to meet short-term obligations is generally good, its immediate cash reserves are more limited. The future outlook is positive, driven by strong growth and profitability, though its operational efficiency lags behind its otherwise stellar financial performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
57.38
Industry Median
32.74
Mid Cap Median
40.92
P/E RATIO
54.51
P/B RATIO
9.30
Industry Median
3.49
Mid Cap Median
8.10
P/S RATIO
9.35
Industry Median
3.59
Mid Cap Median
7.16
Others
PEG RATIO
4.29
EV/EBITDA RATIO
33.89
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2408.9 as on Jul 16, 2026.
The company is experiencing an exceptional phase of growth. It has achieved outstanding increases in its revenue, profits, and earnings for shareholders. This high-growth trend is visible across all key financial areas, from top-line sales to bottom-line net income. The company is also successfully expanding its asset base to support this rapid expansion. This comprehensive and robust growth signals strong market demand for its products and services and effective execution of its business strategy, positioning it well for the future.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 18.65 | 29.91 | 10.64 | 12.46 | 5.87 |
| Operating Profit Growth Rate | -3.04 | 28.18 | 28.88 | 15.05 | 7.27 |
| Earnings Per Share (EPS) Growth | -13.98 | 6.22 | 34.48 | 18.98 | 4.3 |
| Asset Growth Rate | 16.58 | 36.37 | 12.43 | 6.95 | 16.51 |
| Net Income Growth Rate | -14.03 | 6.22 | 34.88 | 19.35 | 7.42 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 42.18 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 2 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 3 | Gland Pharma Ltd | 7.91 | 41.83 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 4 | Neuland Laboratories Ltd | 7.84 | 75.93 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 5 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 6 | Ajanta Pharma Ltd | 7.72 | 41.06 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 7 | Alembic Pharmaceuticals Ltd | 7.60 | 24.31 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 39.72 | Neutral | 1865.00 | 38.64 | 941.00 |
| 9 | Syngene International Ltd | 7.16 | 50.86 | Overvalued | 918.00 | 7.55 | 317.00 |
| 10 | ERIS Lifesciences Ltd | 7.15 | 30.92 | Neutral | 1120.00 | 17.61 | 648.00 |
| 11 | Ipca Laboratories Ltd | 6.33 | 38.55 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -85.00 | Neutral | 922.00 | 5.26 | -326.00 |
| 13 | Jubilant Pharmova Ltd | 5.71 | 37.02 | Neutral | 1260.00 | 1.25 | 398.00 |
| 14 | Natco Pharma Ltd | 5.69 | 11.52 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 15 | Wockhardt Ltd | 5.07 | 150.65 | Neutral | 652.00 | 19.51 | 199.00 |
| 16 | Pfizer Ltd | 3.45 | 48.81 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤21st Jan 26
Q3 FY26 Earnings Conference Call
NEUTRAL SENTIMENT